Bioasis and Chiesi Group to Host Webcast on July 16, 2020
GUILFORD, CONN., U.S.A. and PARMA, ITALY – BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V;
OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TMplatform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare geneticdiseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit ofChiesi Group, an international research-focused healthcare Group, today announced that the companies will host awebcast presentation and conference call at 1:30 p.m. EDT on Thursday, July 16, 2020 to discuss the previouslyannounced Rare Diseases Strategic Alliance.
On June 29, 2020 Bioasis and Chiesi Global Rare Diseases announced that they entered into a worldwide, exclusivelicensing agreement for the xB3 BBB platform technology in treatment of rare diseases with a focus on four undisclosedlysosomal storage disorders (“LSDs”).
Under the terms of the Research Collaboration and License Agreement (the “Agreement”), Chiesi Group will payBioasis an upfront payment of US$3 million. Bioasis may also be eligible to receive additional development, regulatoryand commercial milestone payments of up to US$138 million, as well as additional royalties on net sales of licensedproducts, pending market approval. Chiesi Group will be responsible for all costs associated with research, developmentand commercialization of the four undisclosed LSD programs.
For those wishing to join the July 16th event, it is highly recommended to access the webcast over the Internet using thefollowing link. A replay of the webcast (using the same link provided) will be available for one month following theconclusion of the event.
If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-604-638-5340 (International Toll). Callers shoulddial-in 5-10 minutes prior to the scheduled start time and simply ask to join the call. A teleconference replay will beavailable for two weeks following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (withinCanada / USA) or +1-604-638-9010 (International Toll) and using the replay access code: 4669.
ON BEHALF OF THE BOARD OF DIRECTORS OF BIOASIS TECHNOLOGIES INC.
Deborah Rathjen, Ph.D., Chair & Chief Executive Officer BTI-CRP
ABOUT LYSOSOMAL STORAGE DISORDERS
Lysosomal storage disorders are inherited metabolic diseases that are characterized by an abnormal build-up ofvarious toxic materials in the body's cells as a result of enzyme deficiencies. The build-up of toxic materials can affectdifferent parts of the body, including the skeleton, brain, skin, heart and central nervous system. There are nearly 50known LSDs. While there has been progress in clinical research to develop treatments in recent years, for most LSDsthere are either no or limited treatment options available.
ABOUT CHIESI GLOBAL RARE DISEASES
Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused onresearch and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works incollaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovativenew treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unitis also a dedicated partner with global leaders in patient advocacy, research and patient care.
ABOUT CHIESI GROUP
Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, andmarkets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&Dorganization is headquartered in Parma (Italy), and is integrated with R&D groups in France, the USA, the UK andSweden to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs nearly 6,000 people.Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com.
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 platform, a proprietary technology forthe delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need.The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. Bioasis’internal pipeline programs are focused on treatments for certain brain cancers and rare diseases, including Gaucher’sDisease Type II, neurodegenerative diseases including Parkinson’s disease and Lewy Body Dementia and neuroinflammatory conditions including pain, epilepsy andMultiple Sclerosis. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under thesymbol “BIOAF.” For more information about the Company, please visit www.bioasis.us.
Certain statements in this press release contain forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may notbe based on historical fact along with other statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similarexpressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information.Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners, the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing and the factthat there can be no certainty over the timing or amount of our receipt of any contingent payments contemplated by anysuch corporate collaborations or licensing arrangements, including pursuant to our licensing agreements with ChiesiGroup and Prothena. Specifically, certain risks and uncertainties that could cause such actual events or results expressedor implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that:products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporateobjectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital;we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we faceincreased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties,you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualifiedin their entirety by this cautionary statement. All forward-looking statements and information made herein are based onour current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of theTSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Deborah Rathjen, Chair and Chief Executive Officer email@example.com
+1 203 533 7082
+61 418 160 425
Berry & Company Public Relations firstname.lastname@example.org
Senior Group Communication Manager Chiesi Group